title: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of lymphomas.
abstract: OBJECTIVE
  Lymphomas are the main form of haematological neoplasms, representing 55.6% of all tumours of the blood. Overall, they account for 5.3% of all malignant tumours (excluding basal and squamous cell skin cancer) in Italy with a prevalence constantly increasing at a rate of 3% per year. From a histological point of view, they represent a vast heterogeneous group of haematological diseases, their staging being based on defined cyto-morphological and anatomo-pathological criteria. Although the combined use of standard approaches can provide good response rates, recurrence is particularly frequent in patients undergoing traditional treatment, with critical and often irreversible side effects such as myelosuppression and a high frequency of opportunistic infections and sterility. Numerous epidemiological studies and preclinical data have for some time now reported the anticancer effects of molecules such as Melatonin, Retinoids, Vitamins E, D3, and C, Somatostatin and prolactin inhibitors in neoplastic diseases. There are, however, very few publications on the combined effects of these substances in vivo.
  
  
  METHODS
  We report an observational study carried out on 55 patients affected by various forms of lymphoma, treated with the biological therapy known as the Di Bella Method (DBM). The 1, 3 and 5-year survival rates are reported, together with any signs of toxicity.
  
  
  RESULTS
  The DBM treatment achieved partial or complete objective responses in a shorter time and in greater percentages if administered as first-line therapy. The adjuvant treatment increased survival time and improved quality of life with respect to the data reported in the literature for the same types and stages of lymphoma.
  
  
  CONCLUSIONS
  Overall, the treatment was well tolerated, with minor and transient side effects. The patients were able to continue the treatment at home, carrying out their normal activities without problems.
authors: Di Bella Foundation, Bologna, Italy. posta@giuseppedibella.it
authors: Giuseppe
authors: G
authors: Di Bella
authors: Biagio
authors: B
authors: Colori
authors: Fabrizio
authors: F
authors: Mascia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006728:Hormones / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008550:Melatonin / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects; D010865:Pilot Projects; D015995:Prevalence; D012176:Retinoids / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects; D016019:Survival Analysis; D014815:Vitamins / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000975:Antioxidants; D006728:Hormones; D012176:Retinoids; D014815:Vitamins; D013004:Somatostatin; D008550:Melatonin; D015282:Octreotide